CN107137450B - Pharmaceutical composition and application thereof - Google Patents

Pharmaceutical composition and application thereof Download PDF

Info

Publication number
CN107137450B
CN107137450B CN201710421448.4A CN201710421448A CN107137450B CN 107137450 B CN107137450 B CN 107137450B CN 201710421448 A CN201710421448 A CN 201710421448A CN 107137450 B CN107137450 B CN 107137450B
Authority
CN
China
Prior art keywords
pharmaceutical composition
astragaloside
mass ratio
ferulic acid
volatile oil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201710421448.4A
Other languages
Chinese (zh)
Other versions
CN107137450A (en
Inventor
黄水清
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangzhou University of Chinese Medicine
Original Assignee
Guangzhou University of Chinese Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangzhou University of Chinese Medicine filed Critical Guangzhou University of Chinese Medicine
Priority to CN201710421448.4A priority Critical patent/CN107137450B/en
Publication of CN107137450A publication Critical patent/CN107137450A/en
Priority to PCT/CN2017/113302 priority patent/WO2018223625A1/en
Application granted granted Critical
Publication of CN107137450B publication Critical patent/CN107137450B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/232—Angelica
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481—Astragalus (milkvetch)

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to the field of medicines, and particularly relates to a pharmaceutical composition and application thereof. A pharmaceutical composition mainly comprises a first component and a second component; wherein the first component is total saponins of radix astragali, and the second component is volatile oil of radix Angelicae sinensis; or the first component is astragaloside IV and the second component is ferulic acid. The application of the pharmaceutical composition in preparing the medicines for preventing and/or treating atherosclerosis. The pharmaceutical composition has remarkable effects on reducing serum cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, serum triglyceride and cardiac ejection fraction; it has the effect of preventing or treating hyperlipidemia. Thereby preventing and treating atherosclerosis and cardiovascular and cerebrovascular diseases.

Description

Pharmaceutical composition and application thereof
Technical Field
The invention relates to the field of medicines, and particularly relates to a pharmaceutical composition and application thereof.
Background
With the change of life style of people, more and more foods with high protein, high cholesterol and high sugar are ingested, so that the incidence rate of hyperlipidemia is in a remarkable rising trend. Hyperlipidemia refers to blood hypercholesteremia (TC) and/or hypertriglyceridemia (TG) or hypo-high density lipoprotein cholesterol (HDL-C). Clinically, the method is divided into: hypercholesterolemia (elevated serum TC), hypertriglyceridemia (elevated serum TG), combined hyperlipidemia (elevated TC, TG), hypohyperlipoproteinemia (reduced serum HDL-C levels).
Hyperlipidemia is a prerequisite for the formation of atherosclerosis, and has obvious correlation with the incidence rate of cardiovascular and cerebrovascular diseases. Therefore, in the prevention and treatment of cardiovascular and cerebrovascular diseases, the prevention and treatment of atherosclerosis is particularly important. How to effectively prevent and control the occurrence and development of atherosclerosis is always the focus and hot spot of the research on prevention and treatment of cardiovascular and cerebrovascular diseases.
Atherosclerosis is a complex pathological process with many influencing factors, and the atypical nature of its early symptoms makes its prevention and treatment difficult. At present, western medicine and western medicine have no ideal prevention and treatment method, although the As treated by the traditional Chinese medicine accumulates abundant clinical experience, the As usually has no symptom or characteristic symptom in early and middle stages because the traditional Chinese medicine emphasizes treatment based on syndrome differentiation, so that the prevention and treatment effect of the disease is influenced by the condition that the As has no symptom or is difficult to distinguish the symptom. How to effectively prevent As is still a difficult point at present, so that finding early medicines for preventing As becomes an important point of treatment strategies.
Disclosure of Invention
The invention aims to provide a pharmaceutical composition and application thereof, which aim to solve the problem of abnormal blood lipid metabolism.
The invention provides a technical scheme that:
a pharmaceutical composition mainly comprises a first component and a second component; wherein the content of the first and second substances,
the first component is total saponins of radix astragali, and the second component is volatile oil of radix Angelicae sinensis; or the first component is astragaloside IV and the second component is ferulic acid.
In a preferred embodiment of the invention, the pharmaceutical composition mainly comprises astragaloside and ferulic acid in a mass ratio of 17.5-18.5: 0.3. Preferably, the mass ratio of the astragaloside IV to the ferulic acid is 18.0: 0.3.
In a preferred embodiment of the invention, the pharmaceutical composition mainly comprises astragaloside and ferulic acid in a mass ratio of 16.0-16.5: 0.4. Preferably, the mass ratio of the astragaloside to the ferulic acid is 16.2: 0.4.
In a preferred embodiment of the invention, the pharmaceutical composition mainly comprises the total saponins of astragalus and the angelica volatile oil in a mass ratio of 16.8-17.5: 5.9. Preferably, the mass ratio of the total saponins of astragalus to the volatile oil of angelica is 17.2: 5.9.
In a preferred embodiment of the present invention, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier or adjuvant.
The invention also provides a technical scheme that:
the application of the pharmaceutical composition in preparing the medicines for reducing cholesterol.
The invention also provides a technical scheme that:
the application of the pharmaceutical composition in preparing the medicine for improving the ejection fraction is provided.
The invention also provides a technical scheme that:
the application of the pharmaceutical composition in preparing the medicine for preventing and/or treating hyperlipidemia.
The invention also provides a technical scheme that:
the application of the pharmaceutical composition in preparing medicines for preventing and/or treating cardiovascular and cerebrovascular diseases.
The invention also provides a technical scheme that:
the application of the pharmaceutical composition in preparing the medicines for preventing and/or treating atherosclerosis.
The pharmaceutical composition and the application thereof provided by the embodiment of the invention have the beneficial effects that:
the pharmaceutical composition has remarkable effects on reducing serum cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, serum triglyceride and cardiac ejection fraction; it has the effect of preventing or treating hyperlipidemia. So as to prevent and treat atherosclerosis and cardiovascular and cerebrovascular diseases.
Detailed Description
In order to make the objects, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below. The examples, in which specific conditions are not specified, were conducted under conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products available commercially.
The pharmaceutical composition and the use thereof according to the embodiments of the present invention will be specifically described below.
A pharmaceutical composition mainly comprises a first component and a second component; wherein the first component is total saponins of radix astragali, and the second component is volatile oil of radix Angelicae sinensis. Or the first component is astragaloside IV and the second component is ferulic acid.
The total astragalosides are main active ingredients in astragalus, and have wide pharmacological actions including anti-inflammation, anti-aging, antivirus, anti-hepatic fibrosis, analgesia, immunoregulation, cardiovascular system action and the like. The saponin components comprise astragalosides I-VIII, isoastragalosides I, II and IV, acetyl astragaloside, soyasaponin I, etc., except astragaloside VIII and soyasaponin I, the other saponins take tetracyclic triterpenoid saponins as aglycones, and the saponins are collectively called total astragalosides or astragalosides.
The angelica volatile oil is an important source of the efficacy of angelica. The radix Angelicae sinensis volatile oil contains more chemical components including palmitic acid and phthalic acid; carvacrol, angelone, n-butyl phthalide lactone and the like.
The radix Angelicae sinensis volatile oil can enhance immune function of immune system, and has effects of improving myocardial ischemia, resisting arrhythmia, and relieving asthma.
The angelica volatile oil provided by the embodiment of the invention is extracted from angelica by a decoction method. Specifically, after the angelica is decocted, the volatile oil of the angelica is extracted by a volatile oil collector, and if necessary, the volatile oil can be extracted and purified.
Furthermore, the research of the inventor finds that the application of the total saponins of astragalus in astragalus and the angelica volatile oil extracted from angelica has good curative effect on preventing and treating hyperlipidemia. Compared with the method that the angelica and the astragalus are directly adopted as the medicines, the Chinese medicinal composition can save materials and treat the diseases in a targeted manner. Preferably, the astragalus total saponins and the angelica volatile oil with the mass ratio of 16.8-17.5:5.9 have obvious effect of reducing high-density lipoprotein cholesterol. Preferably, when the mass ratio of the total saponins of astragalus to the volatile oil of angelica sinensis is 17.2:5.9, the effect of reducing high-density lipoprotein cholesterol is better.
It should be noted that, in other embodiments of the present invention, the mass ratio of the total saponins of astragalus to the volatile oil of angelica sinensis can also be 12.9:8.9, 19.4:4.4, 21.6:3.0, and experiments by the inventors show that the medicament obtained from the total saponins of astragalus and the volatile oil of angelica sinensis in the above mass ratio has a significant effect on prevention or treatment of hyperlipidemia.
Astragaloside IV is a cycloartane type triterpenoid saponin compound, and is one of the main effective components in traditional Chinese medicine radix astragali. Astragaloside IV has wide pharmacological effects in resisting tumor, inflammation, oxidation, blood sugar, myocardium, viral myocarditis, brain tissue, and hepatitis B virus.
Astragaloside IV has protective effect on brain injury caused by transient ischemia of mice. In addition, astragaloside iv acts on hepatic glucolase regulation in streptococci and high fat diet induced diabetic rats.
Ferulic acid is an aromatic acid commonly existing in the plant world, is a component of suberin, rarely exists in a free state in the plant body, and mainly forms a combined state with oligosaccharide, polyamine, lipid and polysaccharide. Ferulic acid can increase coronary blood flow, protect ischemic myocardium, and inhibit aortic smooth muscle contraction due to its alpha receptor blocking effect. Sodium ferulate is beneficial to improving oxygen supply and demand imbalance of myocardium. Also has platelet aggregation inhibiting effect.
The research of the inventor finds that when the mass ratio of the astragaloside IV to the ferulic acid is in the range of 17.5-18.5:0.3, the pharmaceutical composition has remarkable curative effect on reducing low-density lipoprotein cholesterol, and preferably, the mass ratio of the astragaloside IV to the ferulic acid is 18.0: 0.3.
Further, in a preferred embodiment of the present invention, the pharmaceutical composition mainly comprises astragaloside and ferulic acid in a mass ratio of 16.0-16.5: 0.4. Preferably, the mass ratio of the astragaloside to the ferulic acid is 16.2: 0.4. In particular, after research, the inventor finds that the pharmaceutical composition prepared at the ratio has a remarkable effect on reducing serum triglyceride.
In addition, in other embodiments of the invention, the mass ratio of astragaloside to ferulic acid can also be 10.8:0.8, 14.4:0.5 and the like.
Further, one or more solid or liquid pharmaceutical excipients and/or adjuvants may be added to the above-mentioned drugs in combination to make a suitable administration form or dosage form for human use.
The pharmaceutical composition provided by the invention can be administered in unit dosage form, and the administration route can be intestinal tract or parenteral tract, such as nasal cavity, subcutaneous, muscle, oral administration and the like. Accordingly, dosage forms such as tablets, capsules, aerosols, pills, powders, solutions, and the like are administered. Can be common preparation, sustained release preparation, controlled release preparation, etc.
In a preferred embodiment of the present invention, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier or adjuvant.
In order to support the tablets from a unit dosage form, a wide variety of carriers well known in the art can be used. As examples of the carrier, diluents and absorbents; such as starch, dextrin, lactose, sucrose, aluminum silicate, and the like. Wetting agents and binders, such as water, glycerol, polyethylene glycol, gelatin syrup, methyl cellulose, and the like. Disintegrating agents, such as alginates, agar powder, sodium bicarbonate, sodium dodecylsulfate, and the like.
As mentioned above, in order to prepare the administration unit into an injectable preparation such as a solution, an emulsion, a lyophilized powder or a suspension, all diluents commonly used in the art, such as water, ethanol, 1, 3-propanediol, polyoxyethylene sorbitol fatty acid, etc., can be used. In addition, to prepare an isotonic injection, an appropriate amount of sodium chloride, glucose or glycerin, and a conventional cosolvent, a buffer, a Ph adjuster, and the like may be added to the preparation for injection.
The dosage of the pharmaceutical composition provided by the embodiments of the present invention to be administered depends on many factors, such as the nature and severity of the disease to be prevented or treated, the sex, age, weight and individual response of the patient or animal. The specific compound used, the route of administration and the number of administrations, etc. Further, the above dose may be administered as a single dose or divided into several, e.g., two, three or four, dose forms.
The invention also provides a technical scheme that: the application of the pharmaceutical composition in preparing the medicines for reducing serum cholesterol. Preferably, in a preferred embodiment of the present invention, the astragaloside IV and ferulic acid in a mass ratio of 17.5-18.5:0.3 have a better effect in the preparation of a medicament for reducing serum cholesterol.
The invention also provides a technical scheme that: the application of the pharmaceutical composition in preparing the medicine for improving the ejection fraction is provided. Furthermore, in the preferred embodiment of the invention, the astragaloside and ferulic acid with the mass ratio of 17.5-18.5:0.3 have better effect in preparing the medicine for improving the ejection fraction of the cardiac function. Preferably, in a preferred embodiment of the invention, the ratio of the amount of astragaloside IV to ferulic acid is 18.0: 0.3.
The invention also provides a technical scheme that: the application of the pharmaceutical composition in preparing the medicine for preventing and/or treating hyperlipidemia. Furthermore, in the preferred embodiment of the invention, the medicament prepared from astragaloside and ferulic acid with the mass ratio of 16.0-16.5:0.4 has a remarkable effect of reducing serum triglyceride. Preferably, the mass ratio of the astragaloside to the ferulic acid is 16.2: 0.4.
The invention also provides a technical scheme that: the application of the pharmaceutical composition in preparing medicines for preventing and/or treating cardiovascular and cerebrovascular diseases. In a preferred embodiment of the present invention, the pharmaceutical composition comprises 16.8-17.5:5.9 mass ratio of total saponins of astragalus to volatile oil of angelica sinensis, preferably 17.2:0.5 mass ratio of total saponins of astragalus to volatile oil of angelica sinensis. The pharmaceutical composition has a remarkable effect on reducing high-density lipoprotein cholesterol.
The invention also provides a technical scheme that: the application of the pharmaceutical composition in preparing the medicines for preventing and/or treating atherosclerosis. In a preferred embodiment of the invention, the pharmaceutical composition comprises astragaloside and ferulic acid in a ratio of 17.5-18.5:0.3, preferably in a quantitative ratio of astragaloside to ferulic acid of 18.0: 0.3. The pharmaceutical composition has a remarkable effect on reducing high-density lipoprotein cholesterol.
The pharmaceutical compositions and uses provided by the present invention are further described in detail below with reference to examples.
Example 1
The embodiment provides a pharmaceutical composition, which mainly comprises total saponins of astragalus and volatile oil of angelica. Wherein the mass ratio of the total saponins of astragalus to the volatile oil of angelica is 16.8: 5.9.
Example 2
The embodiment provides a pharmaceutical composition, which mainly comprises total saponins of astragalus and volatile oil of angelica. Wherein the mass ratio of the total saponins of astragalus to the volatile oil of angelica is 17.5: 5.9.
Example 3
The embodiment provides a pharmaceutical composition, which mainly comprises total saponins of astragalus and volatile oil of angelica. Wherein the mass ratio of the total saponins of astragalus to the volatile oil of angelica is 17.2: 5.9.
Example 4
The embodiment provides a pharmaceutical composition, which mainly comprises total saponins of astragalus and volatile oil of angelica. Wherein the mass ratio of the total saponins of astragalus to the volatile oil of angelica is 12.9: 8.9.
Example 5
The embodiment provides a pharmaceutical composition, which mainly comprises total saponins of astragalus and volatile oil of angelica. Wherein the mass ratio of the total saponins of astragalus to the volatile oil of angelica is 19.4: 4.4.
example 6
The embodiment provides a pharmaceutical composition, which mainly comprises total saponins of astragalus and volatile oil of angelica. Wherein the mass ratio of the total saponins of astragalus to the volatile oil of angelica is 21.6: 3.0.
Example 7
The embodiment provides a pharmaceutical composition, which mainly comprises total saponins of astragalus and volatile oil of angelica. Wherein the mass ratio of the astragaloside IV to the ferulic acid is 17.5: 0.3.
Example 8
This example provides a pharmaceutical composition, which is mainly composed of astragaloside and ferulic acid. Wherein the mass ratio of the astragaloside IV to the ferulic acid is 18.5: 0.3.
Example 9
This example provides a pharmaceutical composition, which is mainly composed of astragaloside and ferulic acid. Wherein the mass ratio of the astragaloside IV to the ferulic acid is 18.0: 0.3.
Example 10
This example provides a pharmaceutical composition, which is mainly composed of astragaloside and ferulic acid. Wherein the mass ratio of the astragaloside IV to the ferulic acid is 16.0: 0.4.
Example 11
This example provides a pharmaceutical composition, which is mainly composed of astragaloside and ferulic acid. Wherein the mass ratio of the astragaloside IV to the ferulic acid is 16.5: 0.4.
Example 12
This example provides a pharmaceutical composition, which is mainly composed of astragaloside and ferulic acid. Wherein the mass ratio of the astragaloside IV to the ferulic acid is 16.2: 0.4.
Example 13
This example provides a pharmaceutical composition, which is mainly composed of astragaloside and ferulic acid. Wherein the mass ratio of the astragaloside IV to the ferulic acid is 10.8: 0.8.
Example 14
This example provides a pharmaceutical composition, which is mainly composed of astragaloside and ferulic acid. Wherein the mass ratio of the astragaloside IV to the ferulic acid is 14.4: 0.5.
Comparative example 1
The comparative example provides a pharmaceutical composition, which mainly comprises astragaloside and ferulic acid. Wherein the mass ratio of the astragaloside IV to the ferulic acid is 8.1: 0.8.
Comparative example 2
The comparative example provides a pharmaceutical composition, which mainly comprises astragaloside and ferulic acid. Wherein the mass ratio of the astragaloside IV to the ferulic acid is 9.0: 0.8.
Comparative example 3
The comparative example provides a pharmaceutical composition, which mainly comprises astragaloside and ferulic acid. Wherein the mass ratio of the astragaloside IV to the ferulic acid is 19.5: 0.3.
Comparative example 4
The comparative example provides a pharmaceutical composition, which mainly comprises astragaloside and ferulic acid. Wherein the mass ratio of the astragaloside IV to the ferulic acid is 22.1: 0.3.
Comparative example 5
The comparative example provides a pharmaceutical composition, which mainly comprises total saponins of astragalus and volatile oil of angelica. Wherein the mass ratio of the total saponins of astragalus to the volatile oil of angelica is 10.4: 8.9.
Comparative example 6
The comparative example provides a pharmaceutical composition, which mainly comprises total saponins of astragalus and volatile oil of angelica. Wherein the mass ratio of the total saponins of astragalus to the volatile oil of angelica is 11.6: 8.9.
Comparative example 7
The comparative example provides a pharmaceutical composition, which mainly comprises total saponins of astragalus and volatile oil of angelica. Wherein the mass ratio of the total saponins of astragalus to the volatile oil of angelica is 22.5: 3.0.
Comparative example 8
The comparative example provides a pharmaceutical composition, which mainly comprises total saponins of astragalus and volatile oil of angelica. Wherein the mass ratio of the total saponins of astragalus to the volatile oil of angelica is 24.2: 3.0.
Test example 1
Examples 1-14 provide pharmaceutical compositions, and comparative examples provide pharmaceutical compositions provided in examples 1-8. Several healthy ICR mice were divided into 24 groups, including a placebo group, a high-fat model group, examples 1-14, and comparative examples 1-8. Applying to an atherosclerosis animal model and a blank group model; water and each test drug are respectively administered by intragastric administration according to the group. The administration was continued for 20 days, and blood was taken on day 21. The concentrations of TC (cholesterol), TG (triglyceride), HDL-C (high density lipoprotein cholesterol) and LDL-C (low density lipoprotein cholesterol) in the blood of each group of mice were measured. Statistical analysis was performed using data processing system SPSS22.0 and the results are shown in table 1.
TABLE 1 examples and effects of comparative examples on blood lipids
Figure BDA0001315021410000131
Figure BDA0001315021410000141
Test example 2
Examples 1-14 provide pharmaceutical compositions, and comparative examples provide pharmaceutical compositions provided in examples 1-8. Several healthy ICR mice were divided into 24 groups, including a placebo group, a high-fat model group, examples 1-14, and comparative examples 1-8. Applying to an atherosclerosis animal model and a blank group model; water and each test drug are respectively administered by intragastric administration according to the group. And (5) analyzing the capability of improving the ejection fraction of the cardiac function. Statistical analysis was performed using data processing system SPSS22.0 and the results are shown in table 2.
Table 2 examples and effects on heart function in comparative myocardial ischemia animal models
Figure BDA0001315021410000151
Figure BDA0001315021410000161
As can be seen from a combination of the results in tables 1 and 2, the pharmaceutical compositions provided in examples 1 to 14 have a significant effect on the prevention or treatment of hyperlipidemia as compared to comparative examples 1 to 8. Preferably, the pharmaceutical composition provided in example 3 has a significant effect on reducing high density lipoprotein cholesterol. The pharmaceutical composition provided in example 9 has significant effects on reducing serum cholesterol, reducing low density lipoprotein cholesterol, and increasing cardiac ejection fraction. Further, the pharmaceutical composition provided in example 12 has a significant therapeutic effect on lowering serum triglycerides.
The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention, and various modifications and changes may be made by those skilled in the art. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims (8)

1. A pharmaceutical composition is characterized by mainly comprising astragaloside and ferulic acid in a mass ratio of 17.5-18.5: 0.3.
2. A pharmaceutical composition is characterized by mainly comprising astragaloside and ferulic acid in a mass ratio of 16.0-16.5: 0.4.
3. A pharmaceutical composition is characterized by mainly comprising radix astragali total saponin and radix Angelicae sinensis volatile oil in a mass ratio of 16.8-17.5: 5.9.
4. Use of a pharmaceutical composition according to any one of claims 1 to 3 for the manufacture of a cholesterol-lowering medicament.
5. Use of a pharmaceutical composition according to any one of claims 1 to 3 for the manufacture of a medicament for increasing ejection fraction.
6. Use of the pharmaceutical composition of any one of claims 1-3 for the preparation of a medicament for the prevention and/or treatment of hyperlipidemia.
7. Use of the pharmaceutical composition of any one of claims 1-3 for the preparation of a medicament for the prevention and/or treatment of cardiovascular and cerebrovascular diseases.
8. Use of a pharmaceutical composition according to any one of claims 1 to 3 for the preparation of a medicament for the prevention and/or treatment of atherosclerosis.
CN201710421448.4A 2017-06-07 2017-06-07 Pharmaceutical composition and application thereof Active CN107137450B (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201710421448.4A CN107137450B (en) 2017-06-07 2017-06-07 Pharmaceutical composition and application thereof
PCT/CN2017/113302 WO2018223625A1 (en) 2017-06-07 2017-11-28 Pharmaceutical composition and use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710421448.4A CN107137450B (en) 2017-06-07 2017-06-07 Pharmaceutical composition and application thereof

Publications (2)

Publication Number Publication Date
CN107137450A CN107137450A (en) 2017-09-08
CN107137450B true CN107137450B (en) 2021-02-23

Family

ID=59780200

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201710421448.4A Active CN107137450B (en) 2017-06-07 2017-06-07 Pharmaceutical composition and application thereof

Country Status (2)

Country Link
CN (1) CN107137450B (en)
WO (1) WO2018223625A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112386582B (en) * 2020-11-24 2023-01-13 广州白云山中一药业有限公司 Solid-liquid dual-phase capsule containing astragalus membranaceus and angelica sinensis and preparation method of capsule
CN112656834A (en) * 2021-01-26 2021-04-16 国药集团广东环球制药有限公司 Angelica sinensis and astragalus membranaceus blood replenishing particles and preparation method thereof
CN113171388A (en) * 2021-04-30 2021-07-27 广州中医药大学(广州中医药研究院) Application of total saponins of astragalus or volatile oil of angelica in preparation of reagent for treating diseases related to abnormal protein expression

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102138963B (en) * 2010-02-03 2013-07-03 高建 Chinese angelica and astragalus extract, and preparation method and application thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
当归挥发油对高血脂小鼠动脉粥样硬化的保护作用;吴国泰等;《中药材》;20160930;第39卷(第09期);第2106页最后1段 *
当归补血汤对动脉粥样硬化大鼠血脂的影响;林增炜等;《中医临床研究》;20131231;第5卷(第12期);第20页讨论部分 *
当归补血汤对心衰大鼠血浆脑钠肽及左室射血分数的影响;徐厚谦等;《中国实验方剂学杂志》;20100430;第16卷(第04期);第123页摘要，左栏第1.2节 *
黄芪及其成分防治动脉粥样硬化的研究进展;刘艳等;《疑难病杂志》;20061231;第5卷(第06期);第463页第1.1-1.3节，第464页第3.2节 *
黄芪甲苷对脓毒症小鼠的保护作用研究;莫菁莲;《中国热带医学》;20131231;第13卷(第08期);第941页左栏第1段 *

Also Published As

Publication number Publication date
WO2018223625A1 (en) 2018-12-13
CN107137450A (en) 2017-09-08

Similar Documents

Publication Publication Date Title
CN101612362B (en) Complex preparation for regulating lipid and preventing and curing heart cerebrovascular diseases and preparation method thereof
CN111110824B (en) Medicinal composition for strengthening body resistance and rescuing lung and application thereof
CN107137450B (en) Pharmaceutical composition and application thereof
TWI300352B (en) Water soluble extract from plant of solanum genus and the preparation process thereof, and pharmaceutical composition containing the water soluble extract
CN111773211B (en) Application of haemagglutinin in preparation of anti-rheumatoid arthritis drugs
WO2015027929A1 (en) Traditional chinese medicine composition
WO2013007092A1 (en) Medicament for treatment of coronary heart diseases and angina pectoris and preparation method therefor
CN101849950A (en) Application of rotundic acid in preparing blood lipid regulating medicines
CN105982887A (en) Application of arctigenin in preparing medicine for treating blood hyperviscosity
CN113350390A (en) Total sesquiterpene lactone of saussurea involucrata, preparation method and pharmaceutical application thereof
CN106822152B (en) Pharmaceutical composition and application thereof
CN108379495B (en) Application of galangal extract in preparation of preparation for preventing and/or treating non-alcoholic fatty liver disease
CN104523737B (en) Application of the buddleo-glucoside IV in the medicine for the treatment of NASH and insulin resistance is prepared
CN102772466A (en) Application of chrysanthemum extract
CN102861278B (en) Lipid-lowering extract from effective parts of sharpleaf galangal fruit and preparation and application thereof
CN114377023A (en) Preparation of dianthrone compound and application of dianthrone compound in preventing and treating insulin resistance-related metabolic diseases such as diabetes, hyperlipidemia and the like
CN104138488B (en) A kind of pharmaceutical composition of reducing blood lipid and its application
CN104587047B (en) A kind of Chinese medicine composition for being used to treat cardiovascular and cerebrovascular disease
CN110013474A (en) The new application of fenofibrate and drug for new application
CN111514179B (en) Application of combined application of phellinus igniarius and tripterygium glycosides in delaying focal segmental glomerulosclerosis process
CN102138965B (en) Halenia elliptica D.Don extract and preparation method, pharmaceutical composition and application thereof
WO2023125719A1 (en) Veronica undulata extract as well as preparation method therefor and use thereof
KR102236685B1 (en) Composition for preventing or treating lipid metabolism diseases comprising extract of salvia miltiorrhiza or paeonia lactiflora
CN114272254B (en) Application of combination of glycyrrhetinic acid and paeoniflorin in treating liver injury and liver fibrosis
CN101849918A (en) Vitexin-2''-O-rhamnoside pill and preparation method

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant